Format guide · 14 providers with a non-injectable route
Oral and sublingual GLP-1: what actually exists, and what is being sold
Start with the part most pages on this subject bury. There is no FDA-approved oral tirzepatide. Tirzepatide is approved as an injection and nothing else, so every oral tirzepatide drop, tablet or troche advertised online is a compounded preparation that no regulator has assessed. Semaglutide is the exception: an approved oral form genuinely exists. Those two facts do most of the work on this page, and they are the reason it is not simply a ranked list of shops.
Three different things
“Oral GLP-1” is used online to mean all of these interchangeably. They are not interchangeable, and the difference is the difference between an approved medicine and an untested one.
1. Approved oral semaglutide — a real medicine
Rybelsus is FDA-approved oral semaglutide for type 2 diabetes, and an oral semaglutide for weight management has been approved as a tablet. These went through trials and carry labels. Their absorption is achieved with a permeation enhancer built into the formulation, which is a manufacturing solution to a genuinely hard problem — and the reason a compounded drop cannot be assumed to do the same thing. We have written up whether these can sensibly be microdosed in can you microdose Rybelsus.
2. Compounded sublingual and oral preparations — what this page lists
Drops, troches, lozenges and dissolving tablets of semaglutide or tirzepatide, made by compounding pharmacies. Not FDA-approved, not tested as formulations, and with no published absorption data that would let anyone say what fraction of the stated dose reaches the bloodstream. They are legal to prescribe and widely sold. Our longer treatment is do sublingual and troche microdose GLP-1s actually work.
3. Oral tirzepatide — does not exist as an approved product
Eli Lilly has not brought an oral tirzepatide to market. Anything sold under that name is compounded. If a site is advertising “oral tirzepatide” alongside language implying it is Mounjaro in a pill, that is the clearest signal available that its claims deserve no benefit of the doubt.
What this means for the list below. These providers are listed because they publish a non-injectable route and because a reader deliberately taking a small dose has a real, practical reason to want one — splitting a lozenge beats drawing two units into a syringe. That practical advantage is not a claim that the format works as well as the injection. On present evidence it probably does not, and nobody has published the data that would settle it. Intentional GLP-1 microdosing is off-label and unproven in any format; see the evidence review.
Who sells what, by route
Every provider on our roster that publishes a route other than an injection, with the route named as they describe it. A provider is here because of the format it offers, not because we think the format is proven.
Partners first, then everyone else, per our disclosure. The price shown is the provider's headline figure and is not always the figure for the non-injectable option specifically — where a provider prices a drop or a lozenge differently from its injection, that is spelled out on its review page.
01
Found
Not one flat figure · Labs optional · Pharmacy network · Dietitian included · our Found review
None of the compounded oral or sublingual products below are FDA-approved, and none have published absorption data. The prices are real and verified; the equivalence to an injection is not established. Both of those statements are true at once and neither cancels the other.
Top of the partner group
Ordered as everywhere on this site: partners first, then by whether the pricing falls when the dose does.
1
Found
Established, physician-designed weight-care telehealth with a broad formulary, real coaching, and a new GLP-1 microdosing program.
From $99/mo (compounded, varies)
Main trade-off: Compounded semaglutide/tirzepatide are not FDA-approved, and intentional microdosing is off-label and unproven
Full review — 6 strengths, 4 trade-offs+−
Pricing in full: Compounded semaglutide/tirzepatide from $99/mo (entry/microdose; realistic ~$199–$399/mo, cheapest tiers need 3–12-month prepay) · brand path (Wegovy/Ozempic/Zepbound/Mounjaro) adds ~$39/mo membership · oral Rybelsus available · HSA/FSA eligible
Found (joinfound.com, Found Health Inc.) has run physician-designed weight care since 2019 and reports 250k+ members. An intake is reviewed by obesity-medicine clinicians, then care is paired with a behavioral-coaching program — app, 1:1 coaching, and community — plus insurance navigation. The formulary is unusually broad: compounded semaglutide and tirzepatide, brand-name Wegovy/Ozempic/Zepbound/Mounjaro, oral Rybelsus, and even non-GLP oral options, prescribed in all 50 states. In October 2025 Found launched a dedicated GLP-1 microdosing program, which is directly relevant to a start-low approach. Pricing is layered rather than flat: a compounded entry advertised 'as low as $99/mo' (the microdose/entry tier), with realistic ongoing cost around $199–$399/mo, and the cheapest rates requiring a 3–12-month prepay; the brand pathway stacks a ~$39/mo membership on top.
Strengths
Established since 2019 with 250k+ members — a real track record, not a fly-by-night operator
Obesity-medicine clinicians, not just a prescription mill
Broad formulary: compounded semaglutide/tirzepatide, brand Wegovy/Ozempic/Zepbound/Mounjaro, and oral Rybelsus
Dedicated GLP-1 microdosing program (launched Oct 2025) suited to a start-low approach
Real behavioral coaching, app, and community alongside the medication
Insurance navigation, HSA/FSA eligibility, and prescribing in all 50 states
Trade-offs
Compounded semaglutide/tirzepatide are not FDA-approved, and intentional microdosing is off-label and unproven
Layered pricing: the $99/mo figure is the entry/microdose tier — realistic ongoing cost runs higher, and the cheapest rates require a 3–12-month prepay
The brand pathway stacks a ~$39/mo membership fee on top of the medication
Cost and coverage vary meaningfully by state and insurance plan
Visit FoundMicrodosing is off-label and unproven — decide with a clinician. Prices verified in 2026; confirm current terms.
2
telos rx
Sells a microdose as its own named product, priced below its own full dose.
$116/mo micro tirz*
Main trade-off: Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven
Full review — 4 strengths, 4 trade-offs+−
Pricing in full: Microdosed tirzepatide as low as $116/mo (list $279 — the rate depends on plan length) · oral tirzepatide from $129/mo · semaglutide from $99/mo · flat as your dose is titrated
A LegitScript-certified telehealth that publishes four GLP-1 routes side by side and lets a licensed provider match you to one after a five-minute intake. For a low-dose reader the important one is Microdosed Tirzepatide — a genuine separate product at a lower dose and a lower price than the full-dose injection, rather than a full-dose plan you underuse. A needle-free oral tirzepatide sits beside it. The catch is plan length: every figure is an "as low as" that assumes the longest commitment, and the microdose page shows $279 struck through above its $116. Month-to-month you pay near the top of that range, and the site does not publish the intermediate tiers.
Strengths
Sells microdosed tirzepatide as its own SKU, priced BELOW its full-dose tirzepatide — almost nothing else on this board does that
A needle-free daily oral tirzepatide is offered alongside it, so a small dose need not mean part-filling a syringe
Publishes all four routes and their prices on one comparison page, before any intake
LegitScript-certified with US-licensed clinicians, and you pay nothing if a provider decides a GLP-1 is not right for you
Trade-offs
Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven
⚠ Every price is an "as low as" that depends on plan length — the microdose page shows $279 struck through above the $116, and the tiers in between are not published, so a month-to-month microdoser cannot work out their real cost
Pricing outside GLP-1 (peptides, NAD+, HRT) stays hidden until intake
No named clinicians and a thin independent review footprint
Visit telos rxMicrodosing is off-label and unproven — decide with a clinician. Prices verified in 2026; confirm current terms.
The questions people actually ask
Is there an FDA-approved oral tirzepatide?
No. Tirzepatide is approved only as a subcutaneous injection, sold as Mounjaro and Zepbound. Every oral or sublingual tirzepatide product advertised online is compounded, which means it has not been reviewed or approved by the FDA for safety, effectiveness or manufacturing quality, and the FDA maintains a public warning about unapproved GLP-1 drugs sold for weight loss. Worth separating from this: an oral GLP-1 pill does now exist. Orforglipron was approved in April 2026 under the brand name Foundayo. It is a different molecule taken as a daily tablet, not tirzepatide in a pill, and a page selling you the latter is not offering you the former.
Is there an approved oral semaglutide?
Yes, and this is where the two molecules genuinely differ. Oral semaglutide is approved as Rybelsus for type 2 diabetes, and an oral form of semaglutide for weight management has been approved as a tablet. Those are real, FDA-approved products with published trial data behind them. They are not the same thing as a compounded semaglutide drop or lozenge, which is what most of the providers on this page sell.
Do sublingual GLP-1 drops and lozenges actually work?
The evidence is thin, and that is the honest answer rather than a hedge. Peptides the size of semaglutide and tirzepatide are poorly absorbed across the lining of the mouth, and the approved oral semaglutide tablet only achieves absorption by including a specific permeation enhancer in a formulation that was developed and tested for the purpose. A compounded drop or troche has had no equivalent testing published. Treat efficacy claims about them with real scepticism.
Why would a microdoser want a non-injectable format anyway?
Divisibility. Taking a deliberately small dose from a vial means drawing a partial unit into a U-100 insulin syringe and reading it correctly at the low end of the scale. Counting drops, or splitting a lozenge, is a more forgiving physical act. That practical advantage is real and is separate from the question of whether the format delivers the drug, which is the part the evidence does not currently support.
How to decide, in one paragraph
If your reason for wanting a non-injectable route is needle aversion, the approved oral semaglutide products are the only option on this page with trial data behind them, and a prescriber can tell you whether you are a candidate. If your reason is that you want to take a deliberately small amount and find a syringe hard to divide, a compounded lozenge or drop does solve that specific problem — while introducing an unknown about how much of the dose is absorbed, which for a dose that is already small is a compounding uncertainty rather than a minor one. And if you were hoping for tirzepatide in a pill, the honest answer is that the approved product does not exist yet, and that no compounded substitute has shown it works.